Five women with lipedema and insulin resistance were treated with a once-weekly injection of exenatide, a medication in the same GLP-1 family as tirzepatide and semaglutide
Critically, GLP-1 receptors exist beyond the pancreas, in the brain, heart, gastrointestinal system, and kidneys
By mimicking GLP-1, Semaglutide enhances insulin secretion, lowers blood sugar levels, and reduces appetite, which can lead to significant weight loss
The SURPASS trial showed that tilsiparatide provided clinically meaningful improvements in glycemic control and weight loss with a favorable safety profile
The FDA emphasizes the importance of reporting adverse events and medication mistakes, especially with compounded formulations